Breakthrough combo therapy trial offers hope for Tough-to-Treat head and neck cancer
NCT ID NCT06976190
Summary
This study is testing whether a new two-drug combination (MRG003 plus pucotenlimab) works better than standard chemotherapy for people with advanced nasopharyngeal cancer that has returned or spread. Researchers will enroll 446 patients whose cancer has worsened after at least one prior treatment. The main goals are to see if the combination helps patients live longer without their cancer growing and if it's safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.